Login / Signup
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Chan Yoon Y Cheah
Loretta J Nastoupil
Sattva S Neelapu
Sheryl G Forbes
Yasuhiro Oki
Nathan H Fowler
Published in:
Blood (2015)
Keyphrases
</>
diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
multiple myeloma
acute lymphoblastic leukemia
acute myeloid leukemia
newly diagnosed
stem cell transplantation